Faculty Summaries
Igor Astsaturov, MD, PhD
Igor Astsaturov, MD, PhD
Assistant Professor
  • Attending Physician, Medical Oncology

Publications

  • Astsaturov IA, Gordon RA, Cescon TP, Cheng JD, Engstrom PF, Lewis NL, Bromberg M, Weiner LM, Meropol NJ, Cohen SJ. Phase II and Coagulation Study of Bevacizumab with or without Docetaxel in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma. Am J Clinical Oncology. Forthcoming 2009.
  • Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal. 2009 Aug;21(8):1255-68.
  • Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009 Mar;13(3):339-62.
  • Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res. 2008;139:135-52.
  • Panikkar RP, Astsaturov I, Langer CJ. The emerging role of cetuximab in head and neck cancer: a 2007 perspective. Cancer Invest. 2008 Feb;26(1):96-103.
  • Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
  • Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. Review. Erratum in: Expert Opin Ther Targets. 2009 Sep;13(9):1135.
  • Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2006 Dec;6(8):691-710.
  • Astsaturov I, Cohen RB, Harari P. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Sep;6(9):1179-93.
  • Spaner DE, Astsaturov I, Vogel T, Petrella T, Elias I, Burdett-Radoux S, Verma S, Iscoe N, Hamilton P, Berinstein NL. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer. 2006 Feb 15;106(4):890-9.
  • Snyder LC, Astsaturov I, Weiner LM. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.
  • Astsaturov I, Petrella T, Bagriacik EU, de Benedette M, Uger R, Lumber G, Berinstein N, Elias I, Iscoe N, Hammond C, Hamilton P, Spaner DE. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res. 2003 Oct 1;9(12):4347-55.
  • Winer S, Astsaturov I, Cheung R, Tsui H, Song A, Gaedigk R, Winer D, Sampson A, McKerlie C, Bookman A, Dosch HM. Primary Sj�gren's syndrome and deficiency of ICA69. Lancet. 2002 Oct 5;360(9339):1063-9.
  • Winer S, Astsaturov I, Gaedigk R, Hammond-McKibben D, Pilon M, Song A, Kubiak V, Karges W, Arpaia E, McKerlie C, Zucker P, Singh B, Dosch HM. ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide. J Immunol. 2002 Jan 1;168(1):475-82.
  • Winer S, Astsaturov I, Cheung RK, Schrade K, Gunaratnam L, Wood DD, Moscarello MA, O'Connor P, McKerlie C, Becker DJ, Dosch HM. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. J Immunol. 2001 Apr 1;166(7):4751-6.
  • Winer S, Astsaturov I, Cheung R, Gunaratnam L, Kubiak V, Cortez MA, Moscarello M, O'Connor PW, McKerlie C, Becker DJ, Dosch HM. Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis. J Immunol. 2001 Feb 15;166(4):2831-41.
  • Kozyr AV, Kolesnikov AV, Aleksandrova ES, Sashchenko LP, Gnuchev NV, Favorov PV, Kotelnikov MA, Iakhnina EI, Astsaturov IA, Prokaeva TB, Alekberova ZS, Suchkov SV, Gabibov AG. Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol. 1998;75:45-61.
  • Iakhnina EI, Nikitin EA, Astsaturov IA, Varlamova Eiu, Kobzev Iu N, Kovaleva LG, Kremenetskaia AM, Kulikov SM, Melikian AL, Pivnik AV, Samoilova RS, Vorob'ev AI. A benign form of chronic lympholeukemia. Ter Arkh. 1997;69:11-7.
  • Astsaturov IA, Samoilova RS, Iakhnina EI, Pivnik AV, Vorobiov AI. The relevance of cytological studies and Ki-67 reactivity to the clinical course of chronic lymphocytic leukemia. Leuk Lymphoma. 1997;26:337-42.
  • Astsaturov IA, Matutes E, Morilla R, Seon BK, Mason DY, Farahat N, Catovsky D. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia. Leukemia. 1996;10:769-73.
  • Kozyr AV, Kolesnikov AV, Iakhnina EI, Astsaturov IA. DNA-hydrolyzing antibodies in lymphoproliferative disorders. Biull Eksp Biol Med. 1996;121:204-6.